Abstract
<div>Abstract<p><b>Purpose:</b> Dual blockade of HER2 with trastuzumab and lapatinib or pertuzumab has been shown to be superior to single-agent trastuzumab. However, a significant fraction of HER2-overexpressing (HER2<sup>+</sup>) breast cancers escape from these drug combinations. In this study, we sought to discover the mechanisms of acquired resistance to the combination of lapatinib + trastuzumab.</p><p><b>Experimental Design:</b> HER2<sup>+</sup> BT474 xenografts were treated with lapatinib + trastuzumab long-term until resistance developed. Potential mechanisms of acquired resistance were evaluated in lapatinib + trastuzumab-resistant (LTR) tumors by targeted capture next-generation sequencing. <i>In vitro</i> experiments were performed to corroborate these findings, and a novel drug combination was tested against LTR xenografts. Gene expression and copy-number analyses were performed to corroborate our findings in clinical samples.</p><p><b>Results:</b> LTR tumors exhibited an increase in <i>FGF3/4/19</i> copy number, together with an increase in FGFR phosphorylation, marked stromal changes in the tumor microenvironment, and reduced tumor uptake of lapatinib. Stimulation of BT474 cells with FGF4 promoted resistance to lapatinib + trastuzumab <i>in vitro</i>. Treatment with FGFR tyrosine kinase inhibitors reversed these changes and overcame resistance to lapatinib + trastuzumab. High expression of <i>FGFR1</i> correlated with a statistically shorter progression-free survival in patients with HER2<sup>+</sup> early breast cancer treated with adjuvant trastuzumab. Finally, <i>FGFR1</i> and/or <i>FGF3</i> gene amplification correlated with a lower pathologic complete response in patients with HER2<sup>+</sup> early breast cancer treated with neoadjuvant anti-HER2 therapy.</p><p><b>Conclusions:</b> Amplification of FGFR signaling promotes resistance to HER2 inhibition, which can be diminished by the combination of HER2 and FGFR inhibitors. <i>Clin Cancer Res; 23(15); 4323–34. ©2017 AACR</i>.</p></div>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
